|

IO102-103 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1

Indications

  • Head and Neck Squamous Cell Carcinoma1
  • Cancer1

Washington D.C., District of Columbia1 trial

Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).

Sibley Memorial Hospital

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.